QIAGEN N.V. Annual Report 2001

More documents

Recommendations

Info

Contents 2 Report of the Supervisory Board 4 Letter from the Managing Board 6 QIAGEN — Focusing the Power of Life Sciences 16 Contents — Financial Data QIAGEN is the world’s leading provider of innovative technologies for purifying, separating, and handling DNA and RNA — the genetic blueprints of life. Since 1984, QIAGEN has successfully developed, produced, and marketed an everincreasing range of proprietary products for academic, industrial, and clinical research. With the sequencing of the entire human genome in 2000, new applications in the life sciences are rapidly emerging. The developing genomics, proteomics, and cellomics markets are fueling applications such as real-time PCR, microarray analysis for gene and drug discovery, DNA- and RNA-based molecular diagnostics, and genetic vaccination and gene therapy. The knowledge that could result — for example, full characterization of mutations in a cancer patient’s tumor — may allow clinicians to develop drug treatments personalized for each patient. This will lead to more effective treatments, as well as reducing the time and expense of developing new drugs by improving our understanding of the mode of drug action. However, these emerging applications share crucial prerequisites — technologies that enable the handling, extraction, and purification of DNA and RNA. QIAGEN is uniquely positioned to take full advantage of the wealth of commercial opportunities presented by the life science industry. Already a leader in the life science research market, in 2001 QIAGEN strengthened its position in the genomics, proteomics, cellomics, molecular diagnostics, and gene therapy markets through development of innovative products, strategic alliances with key commercial players, and the acquisition of the Sawady group of companies. 2001 was a year of momentum for QIAGEN and our traditions of innovation, quality, and service continued to be key factors for growth and success in the Company’s core business — technologies and products for the purification, separation, and handling of nucleic acids.
Financial Highlights Financial Highlights Net Sales 280,000 260,000 Pro Forma Net Income 240,000 220,000 38,000 36,000 200,000 180,000 US$ per share 0.26 Pro Forma Diluted Earnings per Share in US$ thousands 34,000 32,000 30,000 28,000 26,000 24,000 22,000 20,000 18,000 16,000 1996 1997 1998 1999 2000 2001 0.24 14,000 0.22 12,000 0.20 10,000 0.18 8,000 0.16 6,000 0.14 4,000 0.12 2,000 0.10 0 0.08 1996 1997 1998 1999 * 2000 ** 2001 *** 0.06 0.04 0.02 0.00 1996 1997 1998 1999 * 2000 ** 2001 *** in US$ thousands 160,000 140,000 120,000 100,000 80,000 60,000 40,000 20,000 0 1 * Excluding the effect of purchased in-process research and development related to the acquisition of Rapigene, Inc. ** Excluding the effect of one-time charges related to the acquisition of Operon Technologies, Inc. *** Excluding the effect of one-time charges as well as expenses related to the acquisition of the Sawady Group
Page 1: QIAGEN N.V. Annual Report 2001 QIAG
Page 5 and 6: Report of the Supervisory Board Eri
Page 7 and 8: Letter from the Managing Board To O
Page 9 and 10: QIAGEN — Focusing the Power of Li
Page 13 and 14: — Cellomics QIAGEN — Focusing t
Page 19 and 20: SELECTED CONSOLIDATED FINANCIAL DAT
Page 21 and 22: RESULTS OF OPERATIONS The following
Page 23 and 24: Operon, and QIAGEN Sciences, Inc. (
Page 25 and 26: as a result, operating costs relate
Page 27 and 28: credit lines totaling $9.6 million
Page 29 and 30: $360,000, based on the year-end int
Page 31 and 32: QIAGEN N.V. AND SUBSIDIARIES CONSOL
Page 39 and 40: in affiliated companies that are 50
Page 41 and 42: n. Financial Instruments In the ord
Page 43 and 44: December 31, 2001 (January 1, 2001
Page 45 and 46: During 1997, the Company purchased
Page 47 and 48: On March 20, 1997, the Company sold
Page 49 and 50: As of December 31, 2001 and 2000, t
Page 51 and 52: Long-term debt consists of the foll
Page 53 and 54:
The Company has elected to adopt SF
Page 55 and 56:
17. LICENSING AGREEMENTS The Compan
Page 57 and 58:
Assets Germany United States Switze
Page 59 and 60:
STATEMENTS OF INCOME FOR THE YEAR E
Page 61 and 62:
7. SHAREHOLDERS’ EQUITY The autho
Page 63 and 64:
OTHER INFORMATION 2. STATUTORY PROF
Page 65 and 66:
1977, Lecturer of Biophysical Chemi
Page 67 and 68:
Since June 27, 1996, the Common Sha
Page 69 and 70:
Corporate Headquarters QIAGEN N.V.
Page 71:
QIAGEN Investor Relations Dr. Solve
show all

QIAGEN N.V. Annual Report 2001

Create successful ePaper yourself

Delete template?

Save as template?